Haverford Trust Company’s GSK GSK Stock Holding History

Haverford Trust Company’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.75M	Sell	49,820 -1,026	-2%	-$55.6K	0.03%	162
2025 Q4	$2.49M	Sell	50,846 -14,002	-22%	-$653K	0.02%	161
2025 Q3	$2.8M	Sell	64,848 -8,411	-11%	-$329K	0.03%	150
2025 Q2	$2.81M	Sell	73,259 -514	-0.7%	-$19.6K	0.03%	154
2025 Q1	$2.86M	Buy	73,773 +56	+0.1%	+$2.05K	0.03%	151
2024 Q4	$2.49M	Sell	73,717 -2,929	-4%	-$105K	0.02%	160
2024 Q3	$3.13M	Sell	76,646 -1,395	-2%	-$57.1K	0.03%	149
2024 Q2	$3M	Sell	78,041 -5,254	-6%	-$221K	0.03%	151
2024 Q1	$3.57M	Sell	83,295 -2,360	-3%	-$97.3K	0.04%	140
2023 Q4	$3.17M	Sell	85,655 -2,688	-3%	-$96.5K	0.04%	137
2023 Q3	$3.2M	Sell	88,343 -593	-0.7%	-$21K	0.04%	127
2023 Q2	$3.17M	Sell	88,936 -9,715	-10%	-$348K	0.04%	126
2023 Q1	$3.51M	Buy	98,651 +1,748	+2%	+$61.2K	0.04%	121
2022 Q4	$3.41M	Sell	96,903 -1,335	-1%	-$44.5K	0.04%	122
2022 Q3	$2.89M	Buy	98,238 +179	+0.2%	+$6.78K	0.04%	127
2022 Q2	$5.34M	Sell	98,059 -1,040	-1%	-$57.4K	0.07%	101
2022 Q1	$5.4M	Sell	99,099 -8,080	-8%	-$439K	0.06%	105
2021 Q4	$5.91M	Buy	107,179 +1,545	+1%	+$80.4K	0.06%	106
2021 Q3	$5.04M	Sell	105,634 -4,468	-4%	-$224K	0.06%	109
2021 Q2	$5.48M	Sell	110,102 -140,916	-56%	-$6.77M	0.06%	110
2021 Q1	$11.2M	Sell	251,018 -5,720	-2%	-$260K	0.14%	76
2020 Q4	$11.8M	Sell	256,738 -3,056	-1%	-$140K	0.17%	69
2020 Q3	$12.2M	Sell	259,794 -32,492	-11%	-$1.63M	0.19%	66
2020 Q2	$14.9M	Buy	292,286 +10,558	+4%	+$542K	0.26%	61
2020 Q1	$13.3M	Sell	281,728 -942	-0.3%	-$50.2K	0.27%	65
2019 Q4	$16.6M	Sell	282,670 -20,852	-7%	-$1.16M	0.27%	67
2019 Q3	$16.2M	Sell	303,522 -5,712	-2%	-$294K	0.28%	66
2019 Q2	$15.5M	Sell	309,234 -1,116	-0.4%	-$56K	0.28%	68
2019 Q1	$16.2M	Buy	310,350 +11,820	+4%	+$591K	0.3%	66
2018 Q4	$14.3M	Sell	298,530 -17,833	-6%	-$878K	0.3%	64
2018 Q3	$15.9M	Sell	316,363 -417,825	-57%	-$21.2M	0.29%	64
2018 Q2	$37M	Buy	734,188 +12,645	+2%	+$637K	0.73%	43
2018 Q1	$35.2M	Buy	721,543 +27,514	+4%	+$1.28M	0.71%	42
2017 Q4	$30.8M	Buy	694,029 +98,356	+17%	+$4.54M	0.6%	55
2017 Q3	$30.2M	Buy	595,673 +4,641	+0.8%	+$235K	0.63%	53
2017 Q2	$31.9M	Buy	591,032 +8,422	+1%	+$449K	0.7%	49
2017 Q1	$30.7M	Buy	582,610 +42,459	+8%	+$2.15M	0.7%	50
2016 Q4	$26M	Sell	540,151 -19,495	-3%	-$963K	0.63%	55
2016 Q3	$30.2M	Sell	559,646 -387	-0.1%	-$21.2K	0.75%	47
2016 Q2	$30.3M	Sell	560,033 -23,833	-4%	-$1.26M	0.76%	50
2016 Q1	$29.6M	Buy	583,866 +16,880	+3%	+$841K	0.77%	47
2015 Q4	$28.6M	Buy	566,986 +3,196	+0.6%	+$163K	0.77%	47
2015 Q3	$27.1M	Buy	563,790 +24,465	+5%	+$1.27M	0.79%	45
2015 Q2	$28.1M	Buy	539,325 +5,007	+0.9%	+$282K	0.77%	46
2015 Q1	$30.8M	Buy	534,318 +23,384	+5%	+$1.34M	0.85%	42
2014 Q4	$27.3M	Sell	510,934 -12,821	-2%	-$717K	0.76%	45
2014 Q3	$30.1M	Buy	523,755 +9,877	+2%	+$606K	0.9%	41
2014 Q2	$34.4M	Buy	513,878 +4,326	+0.8%	+$293K	1.01%	38
2014 Q1	$34M	Sell	509,552 -40,301	-7%	-$2.72M	1.05%	36
2013 Q4	$36.7M	Buy	549,853 +9,590	+2%	+$622K	1.03%	35
2013 Q3	$33.9M	Buy	540,263 +3,697	+0.7%	+$238K	1.23%	29
2013 Q2	$33.5M	Buy	+536,566	New	+$34.1M	1.1%	36

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Haverford Trust Company's GSK Position: Q1 2026 in Review

Haverford Trust Company reduced its GSK (GSK) stake by 2% in Q1 2026, selling an estimated $55.6K and leaving 49,820 shares worth $2.75M. The position accounts for 0.03% of the portfolio, ranked #162.

Haverford Trust Company first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $37M in Q2 2018. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Haverford Trust Company held 49,820 shares of GSK worth $2.75M as of Q1 2026.
Haverford Trust Company sold 1,026 GSK shares in Q1 2026, an estimated $55.6K.
GSK made up 0.03% of Haverford Trust Company's portfolio in Q1 2026, its #162 holding.
Haverford Trust Company first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
Haverford Trust Company's GSK position peaked at $37M in Q2 2018.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Haverford Trust Company's 13F filing for Q1 2026, filed 11 May 2026.